Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure–activity relationship
- 30 January 2025
- journal article
- research article
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (6) , 5153-5183
Abstract
Discoidin domain receptors (DDR) are categorized under tyrosine kinase receptors (RTKs) and play a crucial role in various etiological conditions such as cancer, fibrosis, atherosclerosis, osteoarthritis, and inflammatory diseases. The structural domain rearrangement of DDR1 and DDR2 involved six domains of interest namely N-terminal DS, DS-like, intracellular juxtamembrane, transmembrane juxtamembrane, extracellular juxtamembrane intracellular kinase domain, and the tail portion contains small C-tail linkage. DDR has not been explored to a wide extent to be declared as a prime target for any particular pathological condition. Very few scientific data are available so there is a need to study the receptors and their inhibitors. Still, there did not exist FDA-approved small molecules targeting DDR1 and DDR2 receptors so there is an urgent need to develop potent small molecules. Further, the structural features and ligand specificities encourage the researchers to be fascinated about the DDR and explore them for the mentioned biological conditions. Therefore, in the last few years, researchers have been involved in investigating the potent DDR inhibitors. The current review provides an outlook on the anatomy and physiology of DDR, focusing on the structural features of DDR receptors and the mechanism of signaling pathways. We have also compiled the evolutionary development status of DDR inhibitors according to their chemical classes, biological activity, selectivity, and structure–activity relationship. From biological activity analysis, it was revealed that compounds 64a (selectivity: DDR1) and 103a (selectivity: DDR2) were the most potent candidates with excellent activity with IC50 values of 4.67 and 3.2 nM, respectively. Graphical abstractKeywords
This publication has 95 references indexed in Scilit:
- Advancement of DDR1 and DDR2 Inhibitors: Therapeutic Potential of Bioactive Compounds, Designing Strategies, and Structure‐Activity Relationship (SAR)ChemistrySelect, 2024
- Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationshipMolecular Diversity, 2024
- Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity, Structure‐Activity RelationshipChemistry & Biodiversity, 2023
- An updated literature on BRAF inhibitors (2018–2023)Molecular Diversity, 2023
- Novel potent and highly selective DDR1 inhibitors from integrated lead findingMedicinal Chemistry Research, 2023
- Special issue “The advance of solid tumor research in China”: Discoidin domain receptor 2 promotes colorectal cancer metastasis by regulating epithelial mesenchymal transition via activating AKT signalingInternational Journal of Cancer, 2022
- DDR1 and DDR2: a review on signaling pathway and small molecule inhibitors as an anticancer agentMedicinal Chemistry Research, 2021
- Design and Synthesis of DDR1 Inhibitors with a Desired Pharmacophore Using Deep Generative ModelsChemMedChem, 2020
- Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial–mesenchymal transition programme under hypoxiaThe Journal of Pathology, 2014
- Wnt‐5a and G‐protein signaling are required for collagen‐induced DDR1 receptor activation and normal mammary cell adhesionInternational Journal of Cancer, 2002